Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Nifedipine Versus Intravenous Labetalol for Postpartum Hypertensive Emergency
NCT05139238Phase 4Terminated
- Sponsor
- Columbia University
- Start
- Jul 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of nifedipine GITS and labetalol in hypertensive emergency, hypertension (HTN) and preeclampsia (2 arms), sponsored by Columbia University. Primary endpoint: Time to Initial Blood Pressure Control up to 48 hours. Started Jul 2022; status: terminated.
02
Drugs
nifedipine GITSlabetalol
03
Conditions
hypertensive emergencyhypertension (HTN)preeclampsia
Beyond the preview
Go deeper on NCT05139238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05139238.